« Return to News | R&D Trends

Oncodesign and Ipsen collaborate to battle Parkinson’s target

Monday, January 9, 2012 09:34 AM

Ispen, a global specialty-driven pharmaceutical company, and Oncodesign, a drug discovery company, are collaborating to discover and develop innovative LRRK2 kinase inhibitors as potential therapeutic agents against Parkinson’s disease.

The research collaboration will combine Oncodesign’s Nanocyclix technology for next-generation kinase inhibitors with Ipsen’s expertise in movement disorders. The companies hope research will also provide data for additional uses in other therapeutic areas.

“Today, there is no treatment targeting the underlying pathogenetic mechanism leading to progressive deterioration in [Parkinson’s] patients,” said Claude Bertrand, Ipsen’s executive vice president, R&D and chief scientific officer, noting the importance of the research.

"This agreement allows us to advance our series of attractive LRRK2 inhibitors together with a partner with recognized expertise in CNS research,” said Jan Hoflack, Ph.D., chief scientific officer and leader of Oncodesign's discovery activities. “This is our first drug discovery partnership with a major biopharmaceutical company based on our Nanocyclix technology, validating our ability to identify uniquely potent and selective novel kinase inhibitors for use in Oncology, CNS, and other therapeutic areas."

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

December 17

Medici Global says its Alzheimer's Facebook page demonstrates the need for more early detection trials

Analysts: Expect more equity purchases of CROs in 2013

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

January 2013

Parexel celebrates 30 years of change, growth
CRO's founder and chairman reflects on challenges of the past, present and future

Strategies for increasing patient diversity in trials
Sponsors look to improve racial, ethnic recruitment without going overseas

Already a subscriber?
Log in to your digital subscription.

Purchase the January issue.

Subscribe to The CenterWatch Monthly.

December 2012

Publicity, regulation tightening reins on use of KOLs
Debate rages over need to revamp how sponsors use, pay medical experts

Time may be right to makeover the investigator brochure
Size, complexity prevent critical document from being thoroughly read

Already a subscriber?
Log in to your digital subscription.

Purchase the December issue.

Subscribe to The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.